Adjunctive armodafinil for negative symptoms in adults with schizophrenia: A double-blind, placebo-controlled study

Schizophrenia Research

Volumn 135, Issue 1-3, 2012, Pages 116-122

  Kane, John M ^a   Yang, Ronghua ^b   Youakim, James M ^c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b CEPHALON INC   (United States)

^c Cephalon Inc   (United States)

Author keywords

Armodafinil; Negative symptoms; PANSS; Schizophrenia; Tolerability

Indexed keywords

ARMODAFINIL; OLANZAPINE; PALIPERIDONE; PLACEBO; RISPERIDONE;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CNSVITALSIGNS COGNITIVE BATTERY; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; NEGATIVE SYNDROME; PERSONAL AND SOCIAL PERFORMANCE SCALE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCORING SYSTEM; SIDE EFFECT; SUICIDAL IDEATION; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84857239432     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.11.006     Document Type: Article

References (33)

1. Addington D., Addington J., Schissel B. A depression rating scale for schizophrenics. Schizophr. Res. 1990, 3(4):247-251.
2. Akhondzadeh S., Ghayyoumi R., Rezaei F., Salehi B., Modabbernia A.H., Maroufi A., Esfandiari G.R., Naderi M., Ghebleh F., Tabrizi M., Rezazadeh S.A. Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial. Psychopharmacology (Berl) 2011, 213(4):809-815.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC, (text revision). fourth ed.
4. Apud J.A., Weinberger D.R. Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors. CNS Drugs 2007, 21(7):535-557.
5. Barnes T.R. A rating scale for drug-induced akathisia. Br. J. Psychiatry 1989, 154:673-676.
6. Biedermann F., Fleischhaker W.W. Emerging drugs for schizophrenia. Expert Opin. Emerg. Drugs 2011, 16(2):271-282.
7. Bobes J., Arango C., Garcia-Garcia M., Rejas J. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J. Clin. Psychiatry 2010, 71(3):280-286. for the CLAMORS Study Collaborative Group.
8. Bobo W.V., Woodward N.D., Sim M.Y., Jayathilake K., Meltzer H.Y. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, double-blind, placebo-controlled trial. Schizophr. Res. 2011, 130(1-3):106-113.
9. Buchanan R.W. Persistent negative symptoms in schizophrenia: an overview. Schizophr. Bull. 2007, 33(4):1013-1022.
10. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., Nuechterlein K.H., Laughren T., Levin R., Stover E., Fenton W., Marder S.R. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr. Bull. 2005, 31(1):5-19.
11. Dinges D.F., Arora S., Darwish M., Niebler G.E. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr. Med. Res. Opin. 2006, 22(1):159-167.
12. Erhart S.M., Marder S.R., Carpenter W.T. Treatment of schizophrenia negative symptoms: future prospects. Schizophr. Bull. 2006, 32(2):234-237.
13. Gualtieri C.T., Johnson L.G. Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch. Clin. Neuropsychol. 2006, 21(7):623-643.
14. Guy W. ECDEU Assessment Manual for Psychopharmacology: Revised (DHEW publication number ADM 76-338). US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD 1976, 534-537.
15. Kane J.M., D'Souza D.C., Patkar A.A., Youakim J.M., Tiller J.M., Yang R., Keefe R.S. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J. Clin. Psychiatry 2010, 71(11):1475-1481.
16. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
17. Kirkpatrick B., Fenton W.S., Carpenter W.T., Marder S.R. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr. Bull. 2006, 32(2):214-219.
18. Laughren T., Levin R. Food and drug administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophr. Bull. 2006, 32(2):220-222.
19. Létourneau K., Demers M.F., Simard M., Émond C. A 10-week, double-blind, placebo controlled, cross-over trial of adjunctive modafinil for neurocognitive impairments in schizophrenia. Schizophr. Bull. 2009, 35(1):283.
20. Morosini P.L., Magliano L., Brambilla L., Ugolini S., Pioli R. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr. Scand. 2000, 101(4):323-329.
21. Pierre J.M., Peloian J.H., Wirshing D.A., Wirshing W.C., Marder S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry 2007, 68(5):705-710.
22. Rosenberg R., Bogan R. Armodafinil in the treatment of excessive sleepiness. Nat. Sci. Sleep 2010, 2:95-105.
23. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., Coyle J.T. Neurobiology of schizophrenia. Neuron 2006, 52(1):139-153.
24. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 1982, 39(4):486-487.
25. Schwartz J.R., Roth T., Drake C. Armodafinil in the treatment of sleep/wake disorders. Neuropsychiatric Dis. Treat. 2010, 6:417-427.
26. Scoriels L., Barnett J.H., Soma P.K., Sahakian B.J., Jones P.B. Effects of modafinil on cognitive functions in first episode psychosis [published online ahead of print September 10, 2011]. Psychopharmacology (Berl) 2011, 10.1007/s00213-011-2472-4.
27. Sevy S., Rosenthal M.H., Alvir J., Meyer S., Visweswaraiah H., Gunduz-Bruce H., Schooler N.R. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J. Clin. Psychiatry 2005, 66(7):839-843.
28. Sharafi M. Comparison of classical and clozapine treatment on schizophrenia using Positive and Negative Syndrome Scale of Schizophrenia (PANSS) and SPECT imaging. Int. J. Med. Sci. 2005, 2(2):79-86.
29. Simpson G.M., Angus J.W. A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. 1970, 212:11-19.
30. Turner D.C., Clark L., Dowson J., Robbins T.W., Sahakian B.J. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol. Psychiatry 2004, 55(10):1031-1040.
31. Turner D.C., Clark L., Pomarol-Clotet E., McKenna P., Robbins T.W., Sahakian B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004, 29(7):1363-1373.
32. Umbricht D., Yoo K., Youssef E., Dorflinger E., Martin-Facklam M., Bausch A., Arrowsmith R., Alberati D., Marder S., Santarelli L. Glycine transporter type 1 (GLYT1) inhibitor RG1678: positive results of the proof-of-concept study for the treatment of negative symptoms in schizophrenia. Neuropsychopharmacology 2010, 35(suppl 1):S320-S321.
33. Volkow N.D., Fowler J.S., Logan J., Alexoff D., Zhu W., Telang F., Wang G.J., Jayne M., Hooker J.M., Wong C., Hubbard B., Carter P., Warner D., King P., Shea C., Xu Y., Muench L., Apelskog-Torres K. Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications. JAMA 2009, 301(11):1148-1154.